Given the above-mentioned findings, we studied the impact of the CBP/EP300 bromodomain inhibitor on the expression of ABC transporters, which are highly transcribed in the breast cancer cell line MDA-MB-231 and functionally linked to cancer multidrug resistance. Here, ABCG2 is linked to cancer.